Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma
SM Setayesh et al, NPJ Prec Oncol September 18, 2023
From the abstract: "We analyzed ~87,000 cells from seven patient samples (bone marrow and peripheral blood) across the myeloma disease spectrum and utilized our multiplexed panel to characterize the expression of clinical markers for PC classification, additional potential therapeutic targets, and the tumor microenvironment cells. Our analysis showed BCMA, ICAM3 (CD50), CD221, and CS1 (SLAMF7) as the most abundantly expressed markers on PCs across all myeloma stages, with BCMA, ICAM3, and CD221 having significantly higher expression levels on disease versus precursor PCs. "
Assessing the Clinical Utility of Liquid Biopsies Across 5 Potential Indications From Therapy Selection to Population Screening: A Review.
David J Carr et al. JAMA Intern Med 2023 8
From the abstract: "Circulating tumor DNA tests are being promoted for multiple indications. Numerous studies are ongoing, but randomized clinical trials of their effect on patient-centered outcomes are rare. While these tests have the potential to improve care in selected indications, this must be proven, as they will add cost, complexity, and unintended adverse effects for patients."
Genome-wide mutation profiles from cell-free DNA for early cancer detection
Nature Genetics, July 31, 2023
Through whole-genome sequencing of single molecules of circulating cell-free DNA, we found that tumor-derived mutations in cancer genomes are associated with regions of late replication timing and other chromatin features. These genome-wide analyses identified altered regional mutation profiles in people with cancer that distinguished them from people without cancer and reflected tumor burden during therapy.
Practical recommendations for using ctDNA in clinical decision making.
Stacey A Cohen et al. Nature 2023 7 (7969) 259-268
Early detection of recurrence using blood-based biomarkers such as circulating tumor DNA (ctDNA) is being increasingly used in clinical practice.
Here we provide general recommendations on the clinical utility of ctDNA and how to interpret ctDNA analysis in different treatment settings, especially in patients with solid tumors. Specifically, we provide an understanding around the implications, strengths and limitations of this novel biomarker and how to best apply the results in clinical practice.